<unk>  (INN) is a gonadotropin-releasing hormone agonist (GnRH agonist).  The drug's effects are dependent on the frequency and time course of administration.  GnRH is released in a pulsatile fashion in the postpubertal adult.  Initial interaction of any GnRH agonist, such as<unk> , with the GnRH receptor induces release of FSH and LH by gonadotrophes.  Long-term exposure to constant levels of<unk> , rather than endogenous pulses, leads to downregulation of the GnRH receptors and subsequent suppression of the pituitary release of LH and FSH.
Like other GnRH agonists,<unk>  may be used in the treatment of hormone-responsive cancers such as prostate cancer or breast cancer, estrogen-dependent conditions (such as endometriosis or uterine fibroids), and in assisted reproduction.
It is normally delivered via a nasal spray, but is also available as an injection.<unk>  acetate is marketed by Sanofi-Aventis under the brand name Suprefact and a generic form of<unk>  is now produced by CinnaGen under the brand name CinnaFact.<unk>  is also marketed under the brand name Metrelef. Metrelef is approved to treat patients with endometriosis by suppression of ovarian hormone production. In ovulation induction Metrelef is used as a pituitary blockade as an adjunct to gonadotrophin administration.
Buserelin
Goserelin
Proligeston
Gestodene
Fosfestrol
Leuprolide
Gestrinone
Anastrozole